SCYNEXIS INC (SCYX) Stock Profile — Insider Trades & Financials

Revenue$18.6M

Net Income$12.3M

EPS$-0.17

Market Cap$44.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

David Angulo

CEO & Executive Director

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Founded: 1999
Employees: 18
Headquarters: Jersey City, New Jersey, United States

⚡

Core Efficiency

ROE?

24.83%

ROA?

20.77%

D/E Ratio?

0.20

Op. Margin?

56.42%

📊

Profitability Ratios

Net Margin?

65.74%

Loading company sections...

SCYNEXIS INC

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness